Autosomal Dominant Osteopetrosis Type I

Key Findings

Finding 1 — ADO-I is an LRP5 gain-of-function high-bone-mass disorder (11q13) [human clinical]

Linkage analysis in two Danish ADO-I families mapped the disease locus to chromosome 11q12–13 (summated maximum LOD +6.54 with marker D11S1889; candidate region 6.6 cM between D11S1765 and D11S4113), the interval containing LRP5 (PMID: 12054167). Van Wesenbeeck and colleagues then identified six novel heterozygous missense mutations — D111Y, G171R, A214T, A214V, A242T, and T253I — in the N-terminal region of LRP5 across a spectrum of increased-bone-density conditions including osteopetrosis type I. All cluster in the same region as the previously reported G171V HBM mutation; the mutations are "located in the aminoterminal part of the gene" before the first EGF-like/β-propeller domain (PMID: 12579474). The recognition of these gain-of-function alleles prompted a formal reclassification: "The identification of LRP5 gain-of-function mutations in autosomal dominant osteopetrosis type I prompted a revision of the classification scheme, and this form is now being included among the high-bone-mass diseases" (PMID: 20855225).

This is the central reframing of the disease: ADO-I is not a defect of bone removal but of excessive bone formation driven by a Wnt co-receptor.

Finding 2 — Mechanism: mutant LRP5 resists sclerostin/DKK1, causing constitutive Wnt/β-catenin signaling [in vitro + mouse]

The gain-of-function is a loss of inhibition. In vitro, six different HBM-LRP5 mutants are resistant: "neither Dickkopf1 (DKK1) nor sclerostin efficiently inhibits HBM-LRP5 signaling" (PMID: 18521528); DKK1 and sclerostin act as independent regulators of LRP5, and both are impaired by the HBM mutations. This receptor-resistance model was confirmed in vivo with knock-in mice: "the (8kb) Dmp1-SOST transgene significantly lowered whole-body bone mineral density (BMD), bone mineral content (BMC), femoral and vertebral trabecular bone volume fraction (BV/TV), and periosteal bone-formation rate (BFR) in wild-type mice but not in mice with Lrp5 p.G171V and p.A214V alleles" (PMID: 25808845). The p.A214V allele was more sensitive to DKK1 than p.G171V, indicating mutation-specific, differential inhibitor sensitivity.

Critically, the osteoclast is a bystander. Osteoclasts from a T253I ADO-I patient showed "normal osteoclastogenesis, expression of osteoclast markers, morphology, and localization of proteins involved in bone resorption, such as ClC-7 and cathepsin K. The ability to resorb bone was also normal" in vitro, though they showed decreased resorption and low osteoclast numbers in vivo — consistent with an osteoblast-driven defect that secondarily reduces osteoclastogenic support (PMID: 16251418). Circulating levels of the inhibitors themselves are normal — "There were no significant differences found in the serum levels of sclerostin (SOST), Dickkopf-1 (Dkk-1), or secreted frizzled-related protein-4 (SFRP-4) in affected vs. unaffected individuals" (PMID: 24927689) — confirming the lesion is at the receptor, not in ligand abundance.

Finding 3 — Clinical phenotype: generalized osteosclerosis maximal at the cranial vault, often asymptomatic, uniquely NOT fracture-prone [human clinical]

ADO-I "is characterized by a generalized osteosclerosis, most pronounced at the cranial vault"; patients "are often asymptomatic but some suffer from pain and hearing loss," and — the pathognomonic clinical fact — "ADOI is the only type of osteopetrosis not associated with an increased fracture rate" (PMID: 12054167). Across the overlapping LRP5-HBM/Worth-type endosteal-hyperostosis spectrum (155 reported patients), "Neurological involvement and increased serum alkaline phosphatase (ALP) were present in 19.4% and 3.7% of cases, respectively. Facial changes and torus palatinus were observed in 61% and 41% of cases, respectively" (PMID: 37659026).

The contrast with ADO Type II (Albers-Schönberg disease, caused by CLCN7) is diagnostic: there, "Fractures were common (78% of patients) and healed slowly," with sandwich vertebrae and frequent orthopedic surgery (PMID: 10617161). The Wnt-built ADO-I bone is stronger, not more brittle.

Finding 4 — Markedly increased, age-progressive, cortical-predominant BMD; skull-vault thickening is the defining radiographic feature [human clinical]

Bollerslev and Andersen's original classification of 34 patients showed "Type I showed a pronounced sclerosis of the skull with an enlarged thickness of the cranial wall"; radiogrammetry demonstrated normal subperiosteal width but significantly enlarged cortical thickness (P<0.01) with a reduced medullary cavity, and serum acid phosphatase — a resorption marker — was markedly increased in Type II but not Type I (P<0.01) (PMID: 3377922). DXA of the entire skeleton quantified the magnitude: "Median BMD was markedly increased in the axial skeleton by 51% (44-56) and 42% (33-56), (median differences with 95% CI), respectively, for types I and II compared to normal controls," with no overlap between patient and control ranges and a positive age–BMD correlation in ADO but not controls, indicating progressive osteosclerosis with aging (PMID: 7605703).

Finding 5 — Epidemiology & inheritance: AD, incompletely penetrant, variably expressed; prevalence ≈5.5/100,000 [human clinical]

The Danish Funen County ascertainment gives the best population estimate: "the prevalence was 5.5/100,000 inhabitants. The study disclosed 33 patients of whom 32 had the mild, autosomal dominant form of osteopetrosis. Two obligate carriers, who had the genotype but were not phenotypically affected" — direct evidence of incomplete penetrance (PMID: 3829443). Expressivity is wide and age-dependent: "39% were asymptomatic. The age of first appearance of symptoms also varied widely (8-76 years), with a tendency to increasing symptoms with aging. The frequency of fractures was low" (PMID: 3829443). Transmission is autosomal dominant through heterozygous LRP5 gain-of-function variants (PMID: 12579474); each child of an affected parent has a 50% chance of inheriting the allele, though penetrance is not guaranteed.

Finding 6 — Mouse models: HBM knock-ins reproduce strong bone; Lrp5-knockout does the opposite [mouse]

The genetic direction of effect is mirrored in mice. Transgenic mice carrying human LRP5 G171V "show a similar phenotype with greater bone mass and biomechanical performance than wild-type mice," and nano-indentation showed "The intrinsic material property that reflected the bone modulus was greater (48%) in the HBM as compared to the NTG mice" — the material basis of fracture resistance (PMID: 20503060). The A214V knock-in is "a high bone mass (HBM) mouse (Lrp5(+/p.A214V)) that has increased bone strength from enhanced Wnt signaling," and crossing it into an osteogenesis-imperfecta model raised bone mass and strength (PMID: 27297606). Conversely, Lrp5-knockout mice have low femoral-neck cross-sectional area and BV/TV, opposite to Sost-knockout (PMID: 31437568). Newer transgenic A241T mice (the human A242T equivalent) reproduce the HBM phenotype (PMID: 38909879) and even enhance dental-implant osseointegration (PMID: 41025443).

Finding 7 — Principal morbidity is cranial-nerve compression from skull-base hyperostosis, not fracture [human clinical]

Because bone accrues maximally at the skull, ADO-I morbidity is neuro-compressive. A 26-year-old woman with ADO-I "presented with intractable, electric shock-like facial pain consistent with" trigeminal neuralgia from neurovascular compression compounded by cranial hyperostosis; the report notes "This condition may lead to cranial nerve compression syndromes, with trigeminal neuralgia (TN) occurring infrequently." She was treated durably by staged suboccipital craniectomy/C1 laminectomy plus microvascular decompression, with 5-year sustained relief (PMID: 41431003). More broadly in adult osteopetrosis, "Bone marrow failure, dental abscess, deafness and visual loss are often underestimated and neglected in relation with lack of awareness and expertise" (PMID: 38593953). Because most patients are asymptomatic, the disorder is frequently found incidentally (PMID: 3829443).

Finding 8 — Structural basis: mutations map to the E1 β-propeller, the sclerostin/DKK1 docking module [structural/computational]

The crystal structure of the LRP6 E1 β-propeller revealed it to be a peptide-recognition module: "human missense mutations that result in bone overgrowth (bone mineral density, or BMD, mutations) cluster to the E1 propeller domain of LRP5," and "the consensus E1 binding sequence is a close match to a conserved tripeptide motif present in all Wnt inhibitors that bind LRP5/6. We show that this motif is important for DKK1 and SOST binding to LRP6 and for inhibitory function, providing a detailed structural explanation for the effect of the BMD mutations" (PMID: 21944579). This is the mechanistic keystone: all ADO-I mutations (G171V, D111Y, G171R, A214T/V, A242T, T253I) sit in the exact surface where the inhibitors' NxI tripeptide motif must dock, so the mutant receptor cannot be silenced (PMID: 12579474, PMID: 18521528).

Finding 9 — Diagnosis is radiologic + LRP5 sequencing, with low/normal bone-turnover chemistry [human clinical]

"The diagnosis is radiologic, supported by biochemical and genetic examination to identify mutations in the key genes involved in osteoclasts, TCIRG1, CLCN7, OSTM1, SNX10, RANK, and RANKL" — and, for the HBM/Type I form, LRP5 (PMID: 42096006). Radiographs/CT show generalized osteosclerosis maximal at the cranial vault with cortical thickening and reduced medullary cavity (PMID: 3377922); DXA shows markedly elevated BMD with no overlap with controls (PMID: 7605703). Biochemistry shows normal/low serum acid phosphatase (elevated in Type II), consistent with low turnover (PMID: 3377922, PMID: 3829443). Circulating SOST/DKK1/SFRP-4 are normal and are not diagnostic biomarkers (PMID: 24927689). Radiologists play a key role and must anticipate subtype-specific complications (PMID: 38483591).

Finding 10 — Management is supportive/surgical; the mechanism validates anti-sclerostin/anti-DKK1 osteoporosis drugs [human clinical + mouse]

There is no curative drug. "Treatment is at present largely the management of complications and includes vitamin D and calcium supplements, IFN-γ therapy, and hematopoietic stem cell transplantation (HSCT), the latter being the treatment of choice for most forms of osteopetrosis" — but HSCT targets the osteoclast-defect (recessive) forms and is mechanistically inapplicable to LRP5-driven ADO-I (PMID: 42096006). Symptomatic cranial-nerve compression is managed surgically with durable benefit — "A staged decompressive approach represents an effective and durable treatment option" (PMID: 41431003). The ADO-I mechanism is the therapeutic converse of anabolic osteoporosis therapy: "combined administration of sclerostin and Dkk1 antibody in WT mice produced a synergistic effect on bone gain" (PMID: 29875318) — the very biology that ADO-I patients embody constitutively. Prevention is limited to genetic counseling and cascade testing/surveillance (PMID: 3829443).

Full Section-by-Section Report

1. Disease Information

ADO-I is a rare, mild, autosomal-dominant sclerosing bone dysplasia characterized by generalized osteosclerosis most pronounced at the cranial vault, elevated bone mineral density that increases with age, and — uniquely among the osteopetroses — no increased fracture rate. It is now classified as a high-bone-mass (HBM) disorder driven by LRP5 Wnt-co-receptor gain of function rather than as an osteoclast-resorption defect.

Synonyms / related terms: Osteopetrosis autosomal dominant type 1; ADO-I; LRP5-related high bone mass; Worth-type autosomal dominant endosteal hyperostosis (overlapping spectrum); "benign osteopetrosis" (a partly misleading label, since cranial complications can be serious).

Source of information: Primarily aggregated disease-level resources (OMIM, Orphanet) plus published family and cohort studies; the strongest epidemiologic data derive from a systematic Danish population ascertainment (PMID: 3829443).

2. Etiology

Causal factor — genetic: Heterozygous gain-of-function missense mutations in LRP5. Reported alleles include G171V (the archetypal HBM mutation), D111Y, G171R, A214T, A214V, A242T, and T253I (PMID: 12579474). All localize to the N-terminal first β-propeller (E1) domain (PMID: 21944579).

Genetic risk factors: The causal variant itself is the risk factor; a single heterozygous E1-domain allele is sufficient. No independent susceptibility loci are established. Modifier effects on magnitude and skeletal-surface selectivity differ between alleles (e.g., G171V vs A214V), but combining two HBM alleles does not exceed either alone (PMID: 42113468).

Environmental risk factors: None causally established. Age is a strong modifier of expression — BMD and symptoms increase with age (PMID: 7605703, PMID: 3829443).

Protective factors: Not applicable in the conventional sense. Notably, the mutation itself is "protective" against fracture and osteoporosis — the same biology exploited pharmacologically by anti-sclerostin drugs.

Gene–environment interactions: In Lrp5^A214V mice, the HBM genotype altered the vitamin D endocrine system to maintain high bone mass even under dietary calcium restriction, showing genotype-driven reshaping of calcium handling (PMID: 38477773). This is model-organism evidence of a GxE interaction on peak bone mass.

3. Phenotypes

Severity/progression: Mild, chronic, progressive osteosclerosis; highly variable expressivity with wide age of first symptom (8–76 years) (PMID: 3829443). Quality-of-life impact: Often negligible (asymptomatic majority); when cranial-nerve compression occurs, impact can be significant (chronic pain, deafness, visual loss) but is frequently amenable to surgery (PMID: 41431003, PMID: 38593953).

4. Genetic / Molecular Information

Causal gene: LRP5 (low-density-lipoprotein-receptor-related protein 5), HGNC:6697, OMIM 603506, chromosome 11q13. Pathogenic variants: Heterozygous missense — G171V, D111Y, G171R, A214T, A214V, A242T, T253I — all in the E1 β-propeller (PMID: 12579474). Classification: pathogenic/likely-pathogenic under ACMG (well-established functional gain-of-function, cosegregation, absence in controls). Variant type: missense/single-nucleotide. Allele frequency: extremely rare/absent in gnomAD (private/family-specific). Origin: germline. Functional consequence:* gain of function via loss of inhibitor (SOST/DKK1) binding at E1 (PMID: 18521528, PMID: 21944579).

The loss-of-function pole of the same gene causes osteoporosis-pseudoglioma syndrome (OPPG) — a low-bone-mass phenotype — establishing LRP5 as a bidirectional bone-mass rheostat (PMID: 40940800). In silico analysis of 17 LRP5 nsSNPs found the gain-vs-loss outcome is "primarily dictated by the interaction between the molecule and LRP5, rather than the specific amino acid substitution" (PMID: 40255261).

Modifier genes: allele identity modifies magnitude/surface selectivity (PMID: 42113468). Epigenetic/chromosomal abnormalities: none established. Suggested annotations: LRP5 (HGNC:6697); Wnt-activated receptor activity (GO:0042813).

5. Environmental Information

No environmental toxin, radiation, lifestyle, or infectious agent causes ADO-I; it is a monogenic disorder. The only environmental interaction documented is dietary calcium: HBM-genotype mice maintain high bone mass under calcium restriction by altering vitamin D metabolism (PMID: 38477773). Infectious agents: not applicable.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

1. A heterozygous missense mutation in the E1 β-propeller of LRP5 (e.g., G171V) alters the surface where Wnt-inhibitor peptides dock (PMID: 12579474, PMID: 21944579).
2. This prevents sclerostin (SOST) and DKK1 from binding and inhibiting the receptor (PMID: 18521528; confirmed in vivo, PMID: 25808845).
3. Loss of inhibition results in constitutive Wnt/β-catenin signaling in osteoblast-lineage cells (β-catenin stabilization → nuclear translocation → RUNX2/Osterix activation) (PMID: 17395698, PMID: 39447984).
4. Sustained signaling leads to increased osteoblast proliferation, differentiation, and bone-formation rate (PMID: 25808845).
5. This produces generalized, age-progressive, cortical-predominant osteosclerosis with increased intrinsic material modulus — hence strong, fracture-resistant bone (PMID: 3377922, PMID: 7605703, PMID: 20503060).
6. Branch (osteoclast): osteoblast-derived signals secondarily reduce osteoclast support in vivo, though osteoclasts are intrinsically normal (inferred from patient-cell studies) (PMID: 16251418).
7. Bone accrual is maximal at the skull vault and base, which causes narrowing of cranial foramina and posterior-fossa crowding (PMID: 12054167).
8. This leads to cranial-nerve compression — hearing loss, trigeminal neuralgia, facial palsy, visual compromise — the principal source of morbidity (PMID: 41431003, PMID: 38593953).

Pathway/process detail: Canonical Wnt/β-catenin (KEGG hsa04310; Reactome Wnt signaling). Cellular processes: osteoblast differentiation (GO:0001649), positive regulation of bone mineralization (GO:0030501), Wnt signaling pathway (GO:0016055), positive regulation of osteoblast differentiation (GO:0045669). Protein dysfunction: gain of function via impaired inhibitor docking (not misfolding/aggregation). Cell types: osteoblasts (CL:0000062), osteocytes (CL:0000137, the SOST source), osteoclasts (CL:0000092, bystander). Subcellular: plasma-membrane receptor (GO:0005886); intriguingly the G171V receptor has poor membrane localization yet still causes HBM, so intracellular retention is unlikely to be the operative mechanism (PMID: 42113468).

LRP5 E1 mutation ──► SOST/DKK1 cannot dock ──► constitutive Wnt/β-catenin
│                                             │
│                                             ▼
│                                 ↑ osteoblast bone formation
│                                             │
▼                                             ▼
 (osteoclasts normal) ◄── ↓ secondary support   cortical-predominant osteosclerosis
                                       │
                                       ▼
                        skull-vault / base hyperostosis
                                       │
                                       ▼
                      cranial-nerve compression (morbidity)

7. Anatomical Structures Affected

• Organ/system level: Skeletal system (primary). Cranial vault and skull base most severely affected (UBERON:0001474 bone element; UBERON:0004339 cranial skeletal system). Secondary: cranial nerves (nervous system) via compression; auditory apparatus (hearing loss); optic pathway (visual compromise); dental structures (torus palatinus).
• Tissue/cell level: Cortical bone predominantly (thickened cortex, reduced medullary cavity, PMID: 3377922); osteoblasts (CL:0000062) are the driver cell; osteocytes (CL:0000137) as inhibitor source; osteoclasts (CL:0000092) intrinsically normal.
• Subcellular: LRP5 at the plasma membrane (GO:0005886); β-catenin nuclear signaling (GO:0005634 nucleus).
• Localization/laterality: Bilateral, symmetric, generalized osteosclerosis, cranially accentuated.

8. Temporal Development

• Onset: Variable — childhood through adulthood; the classic AD form often becomes radiographically apparent in adolescence/early adulthood but ranges from 8 to 76 years for first symptoms (PMID: 3829443, PMID: 38483591). Onset pattern is insidious/chronic.
• Progression: Slowly progressive; BMD rises with age (positive age–BMD correlation absent in controls) (PMID: 7605703). Course is stable-to-progressive, lifelong, not relapsing-remitting. No spontaneous remission.
• Critical periods: Peak-bone-mass accrual during growth is amplified by the genotype (PMID: 38477773); surgical intervention windows arise when cranial-nerve compression becomes symptomatic.

9. Inheritance and Population

• Epidemiology: Prevalence of the mild AD osteopetrosis form ≈5.5/100,000 in a Danish population survey (32/33 patients had the AD form) (PMID: 3829443). Incidence not separately quantified.
• Inheritance: Autosomal dominant, heterozygous LRP5 gain of function (PMID: 12579474).
• Penetrance: Incomplete — two obligate carriers were phenotypically unaffected (PMID: 3829443).
• Expressivity: Highly variable, age-dependent (PMID: 3829443).
• Anticipation / mosaicism / founder effects: Not established (non-repeat disorder). Certain alleles (e.g., A242T) recur across multiple families (found in 9 families), but true founder effects are unproven (PMID: 38909879).
• Consanguinity / carrier frequency: Not relevant (dominant); "carrier" ≈ affected allele carrier.
• Demographics: Reported across populations (notably Danish kindreds for ADO-I); no strong sex bias documented; age distribution skews toward detection in adolescence/adulthood.

10. Diagnostics

• Imaging (primary): Skeletal radiographs and CT show generalized osteosclerosis maximal at the cranial vault with cortical thickening and reduced medullary cavity; DXA confirms markedly elevated BMD (no overlap with controls) (PMID: 3377922, PMID: 7605703). Distinguish from ADO-II's rugger-jersey/sandwich vertebrae and endobones (PMID: 10617161).
• Laboratory: Low bone turnover — serum acid phosphatase normal/low in Type I (elevated in Type II); phosphate occasionally low (PMID: 3377922, PMID: 3829443). Serum SOST/DKK1/SFRP-4 are normal — not diagnostic biomarkers (PMID: 24927689).
• Genetic testing: Targeted LRP5 single-gene sequencing (E1 domain) or sclerosing-bone-dysplasia gene panel; WES/WGS where the panel is negative. Radiologic-plus-genetic paradigm (PMID: 42096006). Karyotype/CMA/FISH/mtDNA/repeat testing: not applicable.
• Differential diagnosis: ADO-II (CLCN7, fracture-prone, sandwich vertebrae); pycnodysostosis; sclerosteosis/van Buchem (SOST); Camurati-Engelmann (TGFB1); Worth endosteal hyperostosis (LRP5 spectrum overlap) (PMID: 18328982, PMID: 37659026).
• Screening: Cascade genetic testing of first-degree relatives after an index diagnosis.

11. Outcome / Prognosis

• Survival/mortality: Life expectancy is essentially normal; ADO-I is a "benign" osteopetrosis, in contrast to malignant infantile (recessive) osteopetrosis, though the "benign" label understates cranial risk (PMID: 38483591).
• Morbidity/function: Driven by cranial-nerve compression (hearing loss, trigeminal neuralgia, visual loss), dental abscess, and rare marrow issues — "often underestimated and neglected" (PMID: 38593953). Fractures are NOT increased and bone is intrinsically strong (PMID: 12054167, PMID: 20503060).
• Recovery: Surgical decompression of cranial-nerve compression can give durable relief (5-year sustained) (PMID: 41431003).
• Prognostic factors: Location/severity of cranial hyperostosis and specific allele (magnitude/surface selectivity differ) (PMID: 42113468). No validated molecular prognostic biomarker.

12. Treatment

• Pharmacotherapy: No curative or disease-modifying drug. Supportive vitamin D/calcium; complication management (PMID: 42096006). Anti-resorptives (bisphosphonates/denosumab) are not indicated — resorption is not the problem. (NCIT: vitamin D therapy, calcium supplement.)
• HSCT: The treatment of choice for osteoclast-defect (recessive) osteopetroses, but mechanistically inapplicable to LRP5/osteoblast-driven ADO-I (PMID: 42096006). (NCIT: hematopoietic stem cell transplantation.)
• Surgical/interventional: Decompressive surgery for cranial-nerve compression (e.g., staged posterior-fossa decompression + microvascular decompression for trigeminal neuralgia) — durable (PMID: 41431003); orthopedic surgery for the rare fracture is technically demanding in sclerotic bone. (NCIT: surgical procedure; microvascular decompression.)
• Supportive/rehabilitative: Audiology, ophthalmology, dental care, pain management, multidisciplinary follow-up (PMID: 38593953).
• Therapeutic significance (mirror image): ADO-I biology validated the anti-sclerostin (romosozumab) and anti-DKK1 anabolic osteoporosis strategy — blocking these inhibitors phenocopies the ADO-I gain of function and synergistically raises bone mass (PMID: 29875318, PMID: 17395698, PMID: 39447984).

13. Prevention

• Primary prevention: Not possible (monogenic, germline). Genetic counseling is the mainstay — autosomal dominant, 50% transmission risk per child, with the caveat of incomplete penetrance and variable expressivity (PMID: 3829443).
• Secondary prevention: Cascade testing and periodic surveillance (audiology, ophthalmology, neuro-imaging) to catch cranial-nerve compression early.
• Tertiary prevention: Timely surgical decompression to prevent permanent neural deficit (PMID: 41431003).
• Reproductive options: Preimplantation/prenatal genetic testing available where a familial variant is known. Immunization/public-health/environmental measures: not applicable.

14. Other Species / Natural Disease

• Taxonomy/orthologs: LRP5 is conserved; mouse Lrp5 (NCBI Gene 16973; MGI:1278315) is the principal ortholog used to model the disease.
• Natural disease: No well-characterized spontaneous ADO-I analog is documented in companion animals in the reviewed literature; the strongest cross-species evidence is engineered mouse models (below). Comparative biology: the Wnt/LRP5 bone-mass axis is evolutionarily conserved, and mouse HBM alleles faithfully reproduce the human direction of effect.
• Zoonotic potential: Not applicable (non-infectious, genetic).

15. Model Organisms

Applications: Dissecting Wnt-inhibitor resistance, bone material properties, GxE (dietary calcium/vitamin D), and validating anti-SOST/anti-DKK1 anabolic strategies. Limitations: mouse models capture the HBM/strength phenotype well but do not fully model human skull-base cranial-nerve compression; the G171V membrane-localization paradox remains unresolved (PMID: 42113468). Resources: MGI (mouse Lrp5, MGI:1278315).

Mechanistic Model / Interpretation

ADO-I is best understood as a single-node dysregulation of the Wnt/LRP5 bone-mass rheostat. LRP5 integrates activating Wnt ligands against inhibitory SOST and DKK1 at its E1 β-propeller. In health, osteocyte-derived sclerostin tunes down osteoblast Wnt signaling to keep bone formation in check. ADO-I mutations physically remove the inhibitor "off-switch" from a single receptor surface, so the osteoblast receives an unopposed "build" signal for life. The result is more bone — and, because Wnt-built bone has superior intrinsic material properties, stronger bone. This is the mechanistic explanation for the single most distinctive clinical feature of the disease: it is the only osteopetrosis without excess fractures.

The same node explains the disease's paradoxes: - Osteoclasts are normal because the lesion is upstream in the osteoblast; osteoclast changes seen in vivo are secondary. - Skull-predominant morbidity follows because the skull is where excess formation causes the most mechanical mischief (foraminal narrowing), not because the skull is uniquely susceptible at the molecular level. - Bidirectionality of LRP5 (OPPG at the loss-of-function pole, HBM at the gain-of-function pole) makes ADO-I a natural human experiment that de-risked anti-sclerostin/anti-DKK1 drug development — patients constitutively embody the very pharmacology those drugs deliver.

Evidence Base

Supporting/context papers: 17395698, 39447984, 40940800, 40255261, 38909879, 41025443, 38477773, 31437568, 18328982, 38483591.

Limitations and Knowledge Gaps

1. Nosological overlap. ADO-I, LRP5-HBM, and Worth-type endosteal hyperostosis form a continuum; some cited frequencies (e.g., facial changes 61%, torus palatinus 41%) derive from the broader spectrum rather than genetically confirmed ADO-I alone (PMID: 37659026).
2. Epidemiology is dated and geographically narrow. The 5.5/100,000 prevalence and penetrance estimates rest chiefly on one Danish survey (PMID: 3829443); modern multi-ethnic, genotype-confirmed prevalence and sex-ratio data are lacking.
3. Genotype–phenotype correlation is incomplete. Alleles differ in magnitude and skeletal-surface selectivity, but predictors of who develops cranial-nerve compression are unknown (PMID: 42113468).
4. Mechanistic loose end. The G171V receptor causes HBM despite poor plasma-membrane localization — its mechanism "remains elusive" (PMID: 42113468).
5. No disease-specific therapy or trials. Management is generic/supportive; no ADO-I-targeted pharmacology (e.g., a rational Wnt-dampening approach) has been tested.
6. Biomarkers absent. Circulating Wnt inhibitors are not diagnostic or prognostic (PMID: 24927689); no molecular marker predicts cranial complications.

Proposed Follow-up Experiments / Actions

1. Genotype-stratified natural-history registry. Prospectively enroll genetically confirmed ADO-I patients to quantify per-allele penetrance, age-of-onset distributions, sex ratio, and the incidence/timing of cranial-nerve compression.
2. Predictive imaging biomarkers. Correlate quantitative skull-base CT foraminal metrics with cranial-nerve outcomes to build a risk-stratification tool that triggers earlier prophylactic decompression.
3. Resolve the G171V paradox. Use surface-biotinylation, live-cell receptor trafficking, and structural studies to determine how a poorly membrane-localized receptor drives HBM (PMID: 42113468).
4. Rational therapeutic test in models. Since ADO-I is Wnt-over-signaling, test whether pharmacologic Wnt-inhibitor delivery (recombinant sclerostin/DKK1 agonism or LRP5-E1-targeting antibodies) can selectively dampen skull hyperostosis in A241T/A214V mice without inducing systemic osteopenia.
5. Auditory/ophthalmologic surveillance protocol. Formalize and validate a multidisciplinary screening schedule to catch reversible cranial-nerve deficits early (PMID: 38593953).
6. Comparative-genetics screen. Search veterinary/OMIA resources and companion-animal cohorts for naturally occurring LRP5-HBM analogs to broaden the comparative model base.
7. MONDO/ontology curation. Formalize the ADO-I MONDO entry and precise HP/UBERON/CL annotations (E1-domain gain of function; cranial-nerve compression; osteoblast-driven cortical osteosclerosis) for knowledge-base integration.

Report compiled from a five-iteration autonomous investigation: 10 confirmed findings, 44 papers reviewed. Evidence source types span human clinical (family/cohort/case studies), model organism (knock-in/transgenic/knockout mice), in vitro (receptor-binding assays), and computational (in silico variant analysis, structural biology).

Artifacts

• OpenScientist final report
• OpenScientist final report

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0011001 (2 mentions) - the report calls it "Universal (no overlap with controls)"; HP calls it Increased bone mineral density

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0005886 (2 mentions) - the report calls it "Subcellular: LRP5 at the plasma membrane"; GO calls it plasma membrane**, and lists "cellular membrane" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.